These transgenic mice do not have human amyloid precursor protein (APP) nor do they generate human Aβ, and therefore, lack amyloid toxicity, which is thought to be the main pathological hallmark of Alzheimer’s disease. This evidence concerns the gene APP and early-onset autosomal dominant Alzheimer disease.